[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4981 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 4981
To provide for the issuance of a Lyme Disease Research Semipostal
Stamp.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
August 15, 2025
Mr. Gottheimer (for himself and Mr. Bacon) introduced the following
bill; which was referred to the Committee on Oversight and Government
Reform, and in addition to the Committee on Energy and Commerce, for a
period to be subsequently determined by the Speaker, in each case for
consideration of such provisions as fall within the jurisdiction of the
committee concerned
_______________________________________________________________________
A BILL
To provide for the issuance of a Lyme Disease Research Semipostal
Stamp.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Stamp Out Lyme Disease Act''.
SEC. 2. FINDINGS AND PURPOSE.
(a) Findings.--Congress finds the following:
(1) The Centers for Disease Control and Prevention (CDC)
estimate that 476,000 Lyme disease cases are diagnosed and
treated in the United States annually.
(2) The CDC reports that Lyme disease is difficult to
diagnose due to its diverse manifestations and a lack of
reliable testing options.
(3) The National Institutes of Health (NIH) reports that a
significant number of later-stage or post-treatment Lyme
disease patients are not cured.
(4) The Tick-Borne Disease Working Group reports that 10 to
20 percent of Lyme disease patients will suffer from persistent
symptoms which can be chronic and disabling.
(5) According to the Johns Hopkins Bloomberg School of
Public Health, Lyme disease costs the United States healthcare
system up to $1,300,000,000 per year.
(b) Purpose.--To afford a convenient way for members of the public
to contribute to funding for Lyme disease and related tick-borne
illness research within the National Institute of Allergy and
Infectious Diseases, the United States Postal Service shall issue a
semipostal stamp (hereinafter in this Act referred to as the ``Lyme
Disease Research Semipostal Stamp'') in accordance with this section.
SEC. 3. LYME DISEASE RESEARCH SEMIPOSTAL STAMP.
(a) Terms and Conditions.--The issuance and sale of the Lyme
Disease Research Semipostal Stamp shall be governed by the provisions
of section 416 of title 39, United States Code, and regulations issued
under such section.
(b) Disposition of Proceeds.--
(1) In general.--All amounts becoming available from the
sale of the Lyme Disease Research Semipostal Stamp (as
determined under section 416(d) of such title 39) shall be
transferred to the National Institute of Allergy and Infectious
Diseases, for the purpose described in subsection (a), through
payments which shall be made at least twice a year.
(2) Proceeds not to be offset.--In accordance with section
416(d)(4) of such title 39, amounts becoming available from the
sale of the Lyme Disease Research Semipostal Stamp (as so
determined) shall not be taken into account in any decision
relating to the level of appropriations or other Federal
funding to be furnished in any year to the National Institute
of Allergy and Infectious Diseases.
(c) Duration.--The Lyme Disease Research Semipostal Stamp shall be
made available to the public for a period of at least 6 years,
beginning no later than 12 months after the date of the enactment of
this Act.
(d) Definition.--For purposes of this Act, the term ``semipostal
stamp'' refers to a stamp described in section 416(a)(1) of title 39,
United States Code.
<all>